Sibutramine withdrawal (2010)
Sibutramine, sold as Meridia and Reductil, was an approved obesity drug. A large clinical trial found more heart attacks and strokes among users than among people taking a placebo.
The US Food and Drug Administration asked the maker to withdraw it, and the European Medicines Agency recommended suspending its authorisations.
The drug stayed on the banned list, which is why its presence in a supplement counts as an undisclosed pharmaceutical rather than a labelling slip.
Kurdistan's regulator cited exactly this history when explaining why the three products had to come off shelves.
